What type of urinary incontinence is vaginal estrogen most effective in treating?

Prepare for the NAMS Menopause Certification Exam with a comprehensive quiz. Use flashcards and multiple-choice questions to solidify your understanding. Each question offers hints and explanations to guide your study. Ensure you're ready for success!

Multiple Choice

What type of urinary incontinence is vaginal estrogen most effective in treating?

Explanation:
Vaginal estrogen helps restore the health of urogenital tissues that become thin and less elastic after menopause. By improving the vaginal and urethral mucosa, blood flow, and connective tissue quality, estrogen enhances urethral closure when there’s a sudden increase in intra-abdominal pressure, such as coughing, sneezing, or lifting. This makes leakage less likely in situations driven by urethral sphincter weakness or pelvic floor support problems, which is the hallmark of stress urinary incontinence. Urge incontinence is driven by detrusor overactivity, not tissue atrophy, so estrogen doesn’t address the underlying mechanism there. Mixed incontinence includes a detrusor component, so the benefit is limited. Overflow incontinence stems from obstruction or neurogenic issues rather than tissue atrophy, so estrogen isn’t the primary solution.

Vaginal estrogen helps restore the health of urogenital tissues that become thin and less elastic after menopause. By improving the vaginal and urethral mucosa, blood flow, and connective tissue quality, estrogen enhances urethral closure when there’s a sudden increase in intra-abdominal pressure, such as coughing, sneezing, or lifting. This makes leakage less likely in situations driven by urethral sphincter weakness or pelvic floor support problems, which is the hallmark of stress urinary incontinence.

Urge incontinence is driven by detrusor overactivity, not tissue atrophy, so estrogen doesn’t address the underlying mechanism there. Mixed incontinence includes a detrusor component, so the benefit is limited. Overflow incontinence stems from obstruction or neurogenic issues rather than tissue atrophy, so estrogen isn’t the primary solution.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy